- 1、本文档共14页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
树突状细胞融合瘤苗体内外诱导特异性抗白血病免疫实验探究
树突状细胞融合瘤苗体内外诱导特异性抗白血病免疫实验探究
作者:于津浦,李牧,葛薇,马双,尤胜国
【摘要】 本研究观察615鼠骨髓来源树突状细胞(DC)与白血病细胞L615融合瘤苗L615/DC体内外诱导特异性抗白血病免疫的能力。分别制备615鼠骨髓来源DC,用PEG融合法将DC与照射灭活的L615制备L615/DC融合瘤苗并免疫动物,用MTT法和LDH法测定L615/DC融合瘤苗免疫鼠脾细胞体外MLR反应和对L615特异性杀伤活性,同时通过免疫治疗实验检测L615/DC融合瘤苗的体内抗白血病作用。结果表明:研究获得了具有特征形态的树突状细胞,MLR反应表现出强大的异基因免疫刺激功能,当L615/DC融合瘤苗免疫鼠的脾细胞再次接触L615抗原时表现出强烈的增殖活性;LDH实验显示,融合瘤苗组、共培瘤苗组和灭活L615组均可在体外诱导扩增出L615特异性CTL,但融合瘤苗组的CTL在不同效靶比、不同孵育时间的特异性杀伤活性均明显高于另两组 (Plt;0.01)。体内免疫治疗实验中L615/DC融合瘤苗治疗组平均寿命为25.7±1天,有1/4小鼠长期存活,而对照组全部死亡,平均寿命17.5±1天。2个月后对治疗组存活鼠用致死剂量 L615攻击不发病。结论: L615/DC融合瘤苗可诱导强大的特异性抗L615免疫,它不仅在体外能特异性识别并杀伤L615细胞,还可有效抑制荷瘤鼠体内肿瘤的生长,延长存活时间,并产生免疫记忆,抵抗肿瘤的二次攻击。L615/DC融合瘤苗为肿瘤免疫治疗提供了新的手段。
【关键词】 树突状细胞
Anti-leukemia Immunity Induced by Dendritic Cells Fused with L615 Tumor Cells
Abstract This study was aimed to investigate the specific anti-L615 leukemia cell immunity induced by L615/DC fused cell vaccine in vivo and in vitro. BM-derived DCs were generated from bone marrow of 615 mice by culturing for 9-10 days in culture medium supplemented with GM-CSF and IL-4.Irradiated L615 tumor cells were fused with DC by using PEG to form fused cell vaccine,with which 615 mice were immunized.After immunization,the specific proliferation ability and cytotoxicity against L615 leukemia cells in vitro were examined by MTT and LDH methods.Anti-leukemia effect of fused cell vaccine in vivo was studied by observing the immunotherapy effects on L615 tumor-bearing mice.The results showed that fully mature and functional bone marrow-derived DC were obtained.L615/ DC fused cell vaccine could elicit potent specific proliferation response of spleen T cells from immunized mice when contacting with the same antigen at the second time,and could also elicit the effective cytotoxic activity against L615 leukemia cells in vitro,which were significantly different from other groups.In vivo the average survival time of the tumor-bearing mice received immunotherapy with L615/ DC fused cell vaccine was 25.7±1 days,and one fourth of treat
文档评论(0)